NxStage is a subsidiary of Fresenius Medical Care, a leading provider of kidney care products and services worldwide. NxStage specializes in innovative renal replacement therapies (RRT) to treat patients suffering from chronic kidney failure. The company was founded in 1998 and is headquartered in Lawrence, Massachusetts, United States.

NxStage's flagship product is the System One, a portable hemodialysis machine that allows patients to undergo treatment at home. The System One is designed to be user-friendly, compact, and suitable for use in various settings, including patients' homes, hospitals, and clinics. The device's portability and ease of use provide greater flexibility and independence for patients, enabling them to have more control over their treatment schedule and lifestyle.

On a global scale, NxStage operates in multiple countries, including the United States, Canada, Australia, and several countries in Europe and Asia. The company has established partnerships and joint ventures with various local distributors and healthcare providers to expand its market reach and strengthen its presence in different regions. In terms of market position, NxStage is recognized as a pioneer in home hemodialysis and has gained significant market share in the United States.

The company has successfully differentiated itself by offering innovative solutions that improve patients' quality of life. NxStage's focus on patient-centered care has made it a preferred choice for many individuals needing renal replacement therapy. Throughout its history, NxStage has achieved noteworthy milestones and accomplishments.

In 2018, the company was acquired by Fresenius Medical Care, enabling it to leverage the global infrastructure and resources of its parent company to further expand its market presence and accelerate product development. As of the latest information available, NxStage continues to operate as a subsidiary of Fresenius Medical Care and remains committed to advancing the field of renal therapy. The company's ongoing efforts are centered around developing and improving home hemodialysis technologies to enhance patient outcomes and offer greater treatment access to those in need